[1] |
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases[J]. Cell,2010, 141(7): 1117-1134. DOI: 10.1016/j.cell. 2010. 06.011.
|
[2] |
Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops[J]. Nat Rev Mol Cell Biol, 2011, 12(2): 104-117. DOI: 10.1038/nrm3048.
|
[3] |
Borrero-García LD, Del Mar Maldonado M, Medina-Velázquez J, et al. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer[J]. BMC Cancer, 2021, 21(1): 652. DOI: 10.1186/s12885-021-08366-7.
|
[4] |
Karami E, Soliman H, Ruschin M, et al. Quantitative MRI biomarkers of stereotactic radiotherapy outcome in brain metastasis[J]. Sci Rep, 2019, 9(1): 19830. DOI: 10.1038/s41598-019-56185-5.
|
[5] |
Galldiks N, Kocher M, Ceccon G, et al. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression[J]. Neuro Oncol, 2020, 22(1): 17-30. DOI: 10.1093/neuonc/noz147.
|
[6] |
Koay EJ, Lee Y, Cristini V, et al. A visually apparent and quantifiable CT imaging feature identifies biophysical subtypes of pancreatic ductal adenocarcinoma[J]. Clin Cancer Res, 2018, 24(23): 5883-5894. DOI: 10.1158/1078-0432.Ccr-17-3668.
|
[7] |
Grossmann P, Stringfield O, EL-Hachem N, et al. Defining the biological basis of radiomic phenotypes in lung cancer[J]. Elife, 2017, 6: e23421. DOI: 10.7554/eLife.23421.
|
[8] |
Tu W, Sun G, Fan L, et al. Radiomics signature: a potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology[J]. Lung Cancer, 2019, 132: 28-35. DOI: 10.1016/j.lungcan.2019.03.025.
|
[9] |
Mei D, Luo Y, Wang Y, et al. CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses[J]. Cancer Imaging, 2018, 18(1): 52. DOI: 10.1186/s40644-018-0184-2.
|
[10] |
Zhou J, Tan H, Li W, et al. Radiomics signatures based on multiparametric MRI for the preoperative prediction of the HER2 status of patients with breast cancer[J]. Acad Radiol, 2021, 28(10): 1352-1360. DOI: 10.1016/j.acra.2020.05.040.
|
[11] |
An Z, Aksoy O, Zheng T, et al. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies[J]. Oncogene, 2018, 37(12): 1561-1575. DOI: 10.1038/s41388-017-0045-7.
|
[12] |
Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors[J]. Curr Top Med Chem, 2020, 20(10): 815-834. DOI: 10.2174/1568026620666200303123102.
|
[13] |
Cruz RGB, Madden SF, Brennan K, et al. A transcriptional link between HER2, JAM-A and FOXA1 in breast cancer[J]. Cells, 2022, 11(4): 735. DOI: 10.3390/cells11040735.
|
[14] |
Roviello G, Catalano M, Iannone LF, et al. Current status and future perspectives in HER2 positive advanced gastric cancer[J]. Clin Transl Oncol, 2022, 24(6): 981-996. DOI: 10.1007/s12094-021-02760-0.
|